Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer
•Infusion site extravasation injury is a rare but serious adverse event of tisotumab vedotin.•Central venous access device should be considered in patients with risk factors receiving antibody drug conjugate therapy.•Topical steroids may be used as part of supportive measures.
Authors
- Katherine Cain (ORCID: https://orcid.org/0000-0002-7398-2944)
- Ji Son (ORCID: https://orcid.org/0000-0002-5130-4763)
- Jolyn Taylor (ORCID: https://orcid.org/0000-0003-1267-4371)
- Travis T. Sims (ORCID: https://orcid.org/0000-0003-1975-0795)
- Claire Marten (ORCID: https://orcid.org/0000-0002-2237-8317)
- Kaitlin W Dwyer
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1016/j.gore.2024.101525
- Citations
- 3
- Primary Topic
- Chemotherapy-related skin toxicity
- Type
- article
- Field-Weighted Citation Impact
- 1.60
Funders
- National Cancer Institute